Spectral AI Redefines Burn Evaluation with DeepView AI®Trial Spectral AI, Inc., a leading AI medical diagnostics company listed on NASDAQ, has launched a crucial trial for DeepView AI®, marking a significant step forward in burn evaluation. This key stage, aimed at proving proprietary imaging technology, comes before requesting FDA marketing permission in 2025. With enrollment in national burn centers and emergency departments, Spectral AI redefines clinical wound treatment for both adults and children. The company's commitment to making timely and correct treatment decisions distinguishes it as a pioneer in AI integration for medical diagnostics. Excitingly, $MDAI continues its remarkable run with a 17% pre-trading increase to 3.17. Enter the discussion about how Spectral AI will change the future of health care.
PRESS RELEASE